OCAI
RNA

O'Connor Alternative Investments’s Atrium Therapeutics RNA Stock Holding History

O'Connor Alternative Investments’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-578,011
Closed -$7.73M – 197
2026
Q1 		$7.73M Buy
+578,011
New +$8.12M 0.4% 23

Other funds holding RNA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return

O'Connor Alternative Investments's RNA Position: Q2 2026 in Review

O'Connor Alternative Investments sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 578,011 shares — an estimated $7.73M sold.

O'Connor Alternative Investments first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $7.73M in Q1 2026. 139 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • O'Connor Alternative Investments reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • O'Connor Alternative Investments sold 578,011 Atrium Therapeutics shares in Q2 2026, an estimated $7.73M.
  • O'Connor Alternative Investments first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
  • O'Connor Alternative Investments's Atrium Therapeutics position peaked at $7.73M in Q1 2026.
  • 139 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on O'Connor Alternative Investments's 13F filing for Q2 2026, filed 14 Aug 2026.